Oral Drug Beats Interferon in First Pediatric MS Trial

In the first randomized controlled trial in pediatric multiple sclerosis, fingolimod (Gilenya) significantly cut relapses compared with interferon beta-1a (Avonex), researchers reported here.

• Source: medpagetoday
• 649
• October 30, 2017